Silence Therapeutics plc (SLN) stock forecast & analysis
19.58
NasdaqGM · USDDelayed by 15 minutes
Up: +10.90, +125.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 19.58
- Previous close
- 8.68
- Day range
- 19.56 – 19.61
- 52-week range
- 4.19 – 19.61
- Volume (shares)
- 71.91M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 62.15M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.45
- Market cap
- 1.22B
Market Scanner’s AI analysis of Silence Therapeutics plc (SLN), updated October 2026: Silence Therapeutics' acquisition by Merck KgaA and significant share price surge dominated recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Silence Therapeutics plc (SLN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Silence Therapeutics' acquisition by Merck KgaA and significant share price surge dominated recent analyses.
Recent analyses covered Silence Therapeutics' (SLN) substantial share price increase following a takeover offer from Merck KgaA. The market analyst report detailed technical indicators suggesting an overbought condition and strong short-term momentum, alongside a potential overextended state. The fundamentals analyst report provided a snapshot of the company's financial position, including revenue trends and net losses.
SLN news & sentiment
News reports highlighted a significant positive market reaction to the acquisition offer, with shares surging. Social media discussion focused on the generous terms of the offer and the substantial premium paid premium.
SLN technical picture
The asset showed significant recent upward price trends, trading well above its 50-day and 200-day SMAs, with short-term momentum supported by the 10-day EMA. However, the MACD was below zero, suggesting weakening momentum, and the price trading above the upper Bollinger Band indicated a potential overextended condition.
Fundamentals
The company has reported revenue growth from 2022 to 2024, followed by a decrease in revenue for 2025. Consistent net losses have been reported, with a significant cash balance relative to its debt.
Factors discussed — upside
- Merck KgaA offer at a substantial premium
- Shares surged over 100% in response to acquisition news
- Relative Strength Index (RSI) at 79.48 indicating overbought territory
- Money Flow Index (MFI) at 92.61 suggesting strong buying pressure
- Price trading well above 50-day and 200-day SMAs
Factors discussed — risks
- MACD below zero suggesting weakening momentum
- Current price trading above upper Bollinger Band indicating potential overextension
- Consistent net losses reported
- Revenue decrease in 2025 compared to prior years
- Acquisition news
- Technical indicators
- Financial performance
- Market reaction
Summary updated .
SLN technical indicators
Common technical indicators for SLN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 12.46 | Price above |
| 10-day exponential moving average | 11.35 | Price above |
| Relative strength index (14-day) | 79.48 | Overbought |
| MACD line (12/26/9) | -0.0730 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 6.26 – 15.21 | Price above the upper band |
Analyses
Recent SLN.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-20 SLN.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Silence Therapeutics plc?
- The bull case centers on a significant takeover offer from Merck KgaA, which has driven a substantial surge in the company's share price. Technical indicators also suggested strong buying pressure and upward momentum.
- What are the risks for Silence Therapeutics plc?
- Risks discussed include technical indicators pointing to potential overextension and weakening momentum, alongside a history of net losses and a recent decrease in revenue.
- Is Silence Therapeutics plc bullish or bearish?
- Recent AI analyses of Silence Therapeutics plc examined factors on both sides. Discussed upside: The bull case centers on a significant takeover offer from Merck KgaA, which has driven a substantial surge in the company's share price. Technical indicators also suggested strong buying pressure and upward momentum. Discussed risks: Risks discussed include technical indicators pointing to potential overextension and weakening momentum, alongside a history of net losses and a recent decrease in revenue. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Silence Therapeutics plc?
- News reports highlighted a significant positive market reaction to the acquisition offer, with shares surging. Social media discussion focused on the generous terms of the offer and the substantial premium paid premium.
- How does Market Scanner analyse Silence Therapeutics plc?
- Every analysis of Silence Therapeutics plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Silence Therapeutics plc?
The bull case centers on a significant takeover offer from Merck KgaA, which has driven a substantial surge in the company's share price. Technical indicators also suggested strong buying pressure and upward momentum.
What are the risks for Silence Therapeutics plc?
Risks discussed include technical indicators pointing to potential overextension and weakening momentum, alongside a history of net losses and a recent decrease in revenue.
Is Silence Therapeutics plc bullish or bearish?
Recent AI analyses of Silence Therapeutics plc examined factors on both sides. Discussed upside: The bull case centers on a significant takeover offer from Merck KgaA, which has driven a substantial surge in the company's share price. Technical indicators also suggested strong buying pressure and upward momentum. Discussed risks: Risks discussed include technical indicators pointing to potential overextension and weakening momentum, alongside a history of net losses and a recent decrease in revenue. These are descriptive observations, not a recommendation.
What is the latest sentiment on Silence Therapeutics plc?
News reports highlighted a significant positive market reaction to the acquisition offer, with shares surging. Social media discussion focused on the generous terms of the offer and the substantial premium paid premium.
How does Market Scanner analyse Silence Therapeutics plc?
Every analysis of Silence Therapeutics plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh SLN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.